1,216 research outputs found

    11th German Conference on Chemoinformatics (GCC 2015) : Fulda, Germany. 8-10 November 2015.

    Get PDF

    Interpretable molecular encodings and representations for machine learning tasks

    Get PDF
    Molecular encodings and their usage in machine learning models have demonstrated significant breakthroughs in biomedical applications, particularly in the classification of peptides and proteins. To this end, we propose a new encoding method: Interpretable Carbon-based Array of Neighborhoods (iCAN). Designed to address machine learning models' need for more structured and less flexible input, it captures the neighborhoods of carbon atoms in a counting array and improves the utility of the resulting encodings for machine learning models. The iCAN method provides interpretable molecular encodings and representations, enabling the comparison of molecular neighborhoods, identification of repeating patterns, and visualization of relevance heat maps for a given data set. When reproducing a large biomedical peptide classification study, it outperforms its predecessor encoding. When extended to proteins, it outperforms a lead structure-based encoding on 71% of the data sets. Our method offers interpretable encodings that can be applied to all organic molecules, including exotic amino acids, cyclic peptides, and larger proteins, making it highly versatile across various domains and data sets. This work establishes a promising new direction for machine learning in peptide and protein classification in biomedicine and healthcare, potentially accelerating advances in drug discovery and disease diagnosis

    Gode -- Integrating Biochemical Knowledge Graph into Pre-training Molecule Graph Neural Network

    Full text link
    The precise prediction of molecular properties holds paramount importance in facilitating the development of innovative treatments and comprehending the intricate interplay between chemicals and biological systems. In this study, we propose a novel approach that integrates graph representations of individual molecular structures with multi-domain information from biomedical knowledge graphs (KGs). Integrating information from both levels, we can pre-train a more extensive and robust representation for both molecule-level and KG-level prediction tasks with our novel self-supervision strategy. For performance evaluation, we fine-tune our pre-trained model on 11 challenging chemical property prediction tasks. Results from our framework demonstrate our fine-tuned models outperform existing state-of-the-art models.Comment: It's an ongoing work. We're exploring the ability of Gode on other task

    Computational Approaches to Drug Profiling and Drug-Protein Interactions

    Get PDF
    Despite substantial increases in R&D spending within the pharmaceutical industry, denovo drug design has become a time-consuming endeavour. High attrition rates led to a long period of stagnation in drug approvals. Due to the extreme costs associated with introducing a drug to the market, locating and understanding the reasons for clinical failure is key to future productivity. As part of this PhD, three main contributions were made in this respect. First, the web platform, LigNFam enables users to interactively explore similarity relationships between ‘drug like’ molecules and the proteins they bind. Secondly, two deep-learning-based binding site comparison tools were developed, competing with the state-of-the-art over benchmark datasets. The models have the ability to predict offtarget interactions and potential candidates for target-based drug repurposing. Finally, the open-source ScaffoldGraph software was presented for the analysis of hierarchical scaffold relationships and has already been used in multiple projects, including integration into a virtual screening pipeline to increase the tractability of ultra-large screening experiments. Together, and with existing tools, the contributions made will aid in the understanding of drug-protein relationships, particularly in the fields of off-target prediction and drug repurposing, helping to design better drugs faster

    Graph Neural Networks for Molecular Data

    Get PDF

    Development, validation and application of in-silico methods to predict the macromolecular targets of small organic compounds

    Get PDF
    Computational methods to predict the macromolecular targets of small organic drugs and drug-like compounds play a key role in early drug discovery and drug repurposing efforts. These methods are developed by building predictive models that aim to learn the relationships between compounds and their targets in order to predict the bioactivity of the compounds. In this thesis, we analyzed the strategies used to validate target prediction approaches and how current strategies leave crucial questions about performance unanswered. Namely, how does an approach perform on a compound of interest, with its structural specificities, as opposed to the average query compound in the test data? We constructed and present new guidelines on validation strategies to address these short-comings. We then present the development and validation of two ligand-based target prediction approaches: a similarity-based approach and a binary relevance random forest (machine learning) based approach, which have a wide coverage of the target space. Importantly, we applied a new validation protocol to benchmark the performance of these approaches. The approaches were tested under three scenarios: a standard testing scenario with external data, a standard time-split scenario, and a close-to-real-world test scenario. We disaggregated the performance based on the distance of the testing data to the reference knowledge base, giving a more nuanced view of the performance of the approaches. We showed that, surprisingly, the similarity-based approach generally performed better than the machine learning based approach under all testing scenarios, while also having a target coverage which was twice as large. After validating two target prediction approaches, we present our work on a large-scale application of computational target prediction to curate optimized compound libraries. While screening large collections of compounds against biological targets is key to identifying new bioactivities, it is resource intensive and challenging. Small to medium-sized libraries, that have been optimized to have a higher chance of producing a true hit on an arbitrary target of interest are therefore valuable. We curated libraries of readily purchasable compounds by: i. utilizing property filters to ensure that the compounds have key physicochemical properties and are not overly reactive, ii. applying a similaritybased target prediction method, with a wide target scope, to predict the bioactivities of compounds, and iii. employing a genetic algorithm to select compounds for the library to maximize the biological diversity in the predicted bioactivities. These enriched small to medium-sized compound libraries provide valuable tool compounds to support early drug development and target identification efforts, and have been made available to the community. The distinctive contributions of this thesis include the development and benchmarking of two ligand-based target prediction approaches under novel validation scenarios, and the application of target prediction to enrich screening libraries with biologically diverse bioactive compounds. We hope that the insights presented in this thesis will help push data driven drug discovery forward.Doktorgradsavhandlin

    Machine Learning for Kinase Drug Discovery

    Get PDF
    Cancer is one of the major public health issues, causing several million losses every year. Although anti-cancer drugs have been developed and are globally administered, mild to severe side effects are known to occur during treatment. Computer-aided drug discovery has become a cornerstone for unveiling treatments of existing as well as emerging diseases. Computational methods aim to not only speed up the drug design process, but to also reduce time-consuming, costly experiments, as well as in vivo animal testing. In this context, over the last decade especially, deep learning began to play a prominent role in the prediction of molecular activity, property and toxicity. However, there are still major challenges when applying deep learning models in drug discovery. Those challenges include data scarcity for physicochemical tasks, the difficulty of interpreting the prediction made by deep neural networks, and the necessity of open-source and robust workflows to ensure reproducibility and reusability. In this thesis, after reviewing the state-of-the-art in deep learning applied to virtual screening, we address the previously mentioned challenges as follows: Regarding data scarcity in the context of deep learning applied to small molecules, we developed data augmentation techniques based on the SMILES encoding. This linear string notation enumerates the atoms present in a compound by following a path along the molecule graph. Multiplicity of SMILES for a single compound can be reached by traversing the graph using different paths. We applied the developed augmentation techniques to three different deep learning models, including convolutional and recurrent neural networks, and to four property and activity data sets. The results show that augmentation improves the model accuracy independently of the deep learning model, as well as of the data set size. Moreover, we computed the uncertainty of a model by using augmentation at inference time. In this regard, we have shown that the more confident the model is in its prediction, the smaller is the error, implying that a given prediction can be trusted and is close to the target value. The software and associated documentation allows making predictions for novel compounds and have been made freely available. Trusting predictions blindly from algorithms may have serious consequences in areas of healthcare. In this context, better understanding how a neural network classifies a compound based on its input features is highly beneficial by helping to de-risk and optimize compounds. In this research project, we decomposed the inner layers of a deep neural network to identify the toxic substructures, the toxicophores, of a compound that led to the toxicity classification. Using molecular fingerprints —vectors that indicate the presence or absence of a particular atomic environment —we were able to map a toxicity score to each of these substructures. Moreover, we developed a method to visualize in 2D the toxicophores within a compound, the so- called cytotoxicity maps, which could be of great use to medicinal chemists in identifying ways to modify molecules to eliminate toxicity. Not only does the deep learning model reach state-of-the-art results, but the identified toxicophores confirm known toxic substructures, as well as expand new potential candidates. In order to speed up the drug discovery process, the accessibility to robust and modular workflows is extremely advantageous. In this context, the fully open-source TeachOpenCADD project was developed. Significant tasks in both cheminformatics and bioinformatics are implemented in a pedagogical fashion, allowing the material to be used for teaching as well as the starting point for novel research. In this framework, a special pipeline is dedicated to kinases, a family of proteins which are known to be involved in diseases such as cancer. The aim is to gain insights into off-targets, i.e. proteins that are unintentionally affected by a compound, and that can cause adverse effects in treatments. Four measures of kinase similarity are implemented, taking into account sequence, and structural information, as well as protein-ligand interaction, and ligand profiling data. The workflow provides clustering of a set of kinases, which can be further analyzed to understand off-target effects of inhibitors. Results show that analyzing kinases using several perspectives is crucial for the insight into off-target prediction, and gaining a global perspective of the kinome. These novel methods can be exploited in the discovery of new drugs, and more specifically diseases involved in the dysregulation of kinases, such as cancer
    corecore